# Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy

> **NCT04846673** · PHASE4 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 151 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** Pregabalin 150mg + Alpha-lipoic acid 480mg
- **DRUG:** Pregabalin 150mg
- **DRUG:** Alpha-Lipoic Acid 480mg

## Key facts

- **NCT ID:** NCT04846673
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846673, "Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04846673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*